CN103099903A - Acne therapeutic preparation - Google Patents
Acne therapeutic preparation Download PDFInfo
- Publication number
- CN103099903A CN103099903A CN2013100592688A CN201310059268A CN103099903A CN 103099903 A CN103099903 A CN 103099903A CN 2013100592688 A CN2013100592688 A CN 2013100592688A CN 201310059268 A CN201310059268 A CN 201310059268A CN 103099903 A CN103099903 A CN 103099903A
- Authority
- CN
- China
- Prior art keywords
- acne
- acne therapeutic
- therapeutic agent
- acid
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to an acne therapeutic preparation, which consists of dandelion, herba violae, poria cocos, and radix bupleuri. The preparation has excellent effects on acne caused by long-term work or play till deep into the night, spicy food, bad mood and the like, and can achieve an effect rate up to more than 80%.
Description
Technical field
The present invention relates to a kind of acne therapeutic agent, belong to biomedicine field.
Background technology
Acne is commonly called as comedo, be chronic inflammation pilosebaceous unit disease, be one of modal disease of department of dermatologry, its morbidity is main and sex hormone level, sebaceous gland are secreted in a large number, propionibacterium acnes propagation, the factor analysis such as the dyskeratosis of pilosebaceous duct and inflammation.Be apt to occur in hebetic masculinity and femininity, the male is slightly more than the women, but women's morbidity is early than the male.Have the teenager of 80%-90% to suffer from acne, often can naturally go down or fully recover after adolescence, individual patient also can extend to more than 30 years old.Although acne is the disease that the spontaneous recovery tendency is arranged, the untimely cicatrix that causes of acne itself and acne treatment can have a strong impact on Quality of Life, causes patient's stress and financial burden, need cause concern.Acne is apt to occur in buccal, forehead, buccal and nasolabial fold, is secondly chest, back and shoulder.
According to international improved method, acne is divided into 4 grades:
1. slight (I level): take acne as main, a small amount of papulopustule, total skin lesion is less than 30;
2. moderate (II level): acne are arranged, the pimple of moderate quatity and pustule, total skin lesion is at 30-50;
3. moderate (III level): a large amount of pimples and pustule, accidental large struvite skin lesion, widely distributed, total skin lesion number is between 51-100, and tuberosity is less than 3;
4. severe (IV level): nodositas, cyst and or the property acne, with pain and form cyst, total skin lesion is more than 100, tuberosity or cyst are more than 3.
Acne is an easily disease of recurrence, and the influence factor is a lot, and single therapy often is difficult to receive good effect, need to take Comprehensive Treatment according to the state of an illness.The common oral drugs of Acne treatment mainly contain:
1. antibiotics: oral antibiotic is one of important method of severe acne in treatment, and selecting the antibiotic for the propionibacterium acnes sensitivity is important starting point, first-selected Tetracyclines, and secondly Macrolide, reach therapeutic effect by suppressing its breeding.
2. tretinoin: oral isotretinoin is the standard treatments of the serious acne such as tuberosity cyst type, aggretion type, and its therapeutic effect is remarkable, but also have teratogenesis, blood fat raises and the side effect such as skin mucosa drying, should use under physician guidance.
3. hormones: the effect to androgen antagonist in pathogenesis of acne, reduce sebum secretion and suppress acne and generate, mainly comprise estrogen and the large class of progestogen two, as cyproterone, ethinylestradiol, diethylstilbestrol etc., also have other antagonism androgens medicines such as spironolactone, cimetidine.
4. glucocorticoid: oral glucocorticoid is mainly used in acne fulminans or acne conglobata, plays the effect of immunosuppressant and antiinflammatory.
5. Chinese patent medicine class: coptos bolus for clearing the upper heat, fangfeng tongsheng pill, danzhi xiaoyao pills, Radix Et Rhizoma Rhei Eupolyphaga seu steleophaga ball, ZHIBAI DIHUANG WAN etc.
Local external use's treatment sterilizes as main take degrease, dissolving cutin, antiinflammatory.Commonly used comprises: tretinoin preparation, benzoyl peroxide, erythromycin, chloromycetin, contain sulfur class lotion etc.
Summary of the invention
The purpose of this invention is to provide a kind of acne therapeutic agent, the weak point that exists to solve existing Drug therapy acne.
The technical solution used in the present invention is: a kind of acne therapeutic agent is characterized in that being prepared from by the crude drug of following weight portion:
Herba Taraxaci 9-15 part Herba Violae 15-30 part
Poria 9-15 part Radix Bupleuri 3-9 part
Above-mentioned raw materials also can adopt extract, for example the commercially available extract of above-mentioned raw materials except adopting former powder.
A kind of acne therapeutic agent of the present invention, upper on the basis of mentioned component directly or again adds suitable edible or pharmaceutic adjuvant, can make capsule, tablet, granule, oral liquid, powder, teabag etc.
The above-mentioned edible or pharmaceutic adjuvant that can add comprises: diluent, suspending agent, antioxidant, emulsifying agent, disintegrating agent, adhesive and antiseptic.
Above-mentioned diluent comprises vegetable oil, molecular weight polyethylene glycol 200-6000, the third two liquor-saturated, glycerol, sorbitol, D-xylitol, calcium glycerophosphate, polyvinylpolypyrrolidone, inositol, maltose alcohol, lactobionic acid, cyclodextrin, lactose, calcium oxide, cellulose, glucose, carboxymethyl cellulose, polyvinyl butyral resin etc., and one or more in mineral oil.
Above-mentioned antioxidant comprises one or more in dibenzylatiooluene (BHT), butylated hydroxyarisol (BHA), propyl gallate, tert-butyl hydroquinone (TBHQ), malic acid, glutathion, D-xylose, glycine, a-tocopherol, a-tocopheryl acetate, sodium sulfite, inositol, ascorbic acid, phytic acid, sodium ascorbate, lecithin, hydroquinone, xylitol, succinic acid, tea polyphenols.
Above-mentioned suspending agent comprises one or more in Cera Flava, xanthan gum, arabic gum, casein, methylcellulose, Carboxymethyl cellulose sodium, carbomer, polyvinyl alcohol, hydroxyethyl-cellulose, sodium alginate, chitin, chitose, hydroxypropyl emthylcellulose, ethyl cellulose, agar, hydroxyethylmethyl-cellulose, hyprolose.
Mentioned emulsifier comprises one or more in ethylhydroxyethylcellulose, methylcellulose, glyceryl monostearate, hydroxylated lecithin, the single glycerol vinegar of acetylation, orthoformic acid, casein, ethylene glycol monostearate, diacetyl monoglyceride, acetic acid-fatty acid glycerine vinegar, Emulsifier LM-102, propylene glycol alginate.
Above-mentioned binding agent comprises methylcellulose (MC), polyvinylpyrrolidone (PVP), hydroxypropyl cellulose (HPC), hydroxypropyl emthylcellulose (HPMC), polyvinyl alcohol (PVA), Cellulose Acetate Phthalate (CAP), PVP K30, ethyl cellulose (EC), microcrystalline Cellulose (CC), acrylic resin, Semen Maydis unit, Resina persicae, maltose alcohol, poloxamer; One or more in sodium alginate, liquid glucose, Nulomoline, the acid of sucrose mono laurate.
Above-mentioned disintegrating agent comprises one or more in silica sol, Magnesiumaluminumsilicate, magnesium stearate, pregelatinized starch, cross-linking sodium carboxymethyl cellulose.
Foregoing preservatives comprises one or more in sorbic acid, Sodium Methyl Hydroxybenzoate, benzoic acid, sorbic acid methyl ester, methyl parahydroxybenzoate, P-hydroxybenzoic acid phenyl ester, butyl p-hydroxybenzoate calcium, Oleum Caryophylli, benzyl alcohol, P-hydroxybenzoic acid the third phenol sodium.
Above-mentioned capsule also comprises soft capsule except common gelatin hard-shell capsule.
The specific embodiment
The preparation of embodiment 1. capsules
15 parts of 9 parts of Herba Violaes of Herba Taraxaci
9 parts of 15 parts of Radix Bupleuri of Poria
Pulverize, cross 100 mesh sieves, encapsulated, granulate, and get final product.
The preparation of embodiment 2. oral liquids
25 parts of 12 parts of Herba Violaes of Herba Taraxaci
6 parts of 12 parts of Radix Bupleuri of Poria
Add 30 times of amounts of water, be forced into 300Mpa with hyperpressure extraction equipment, pressurize 5 minutes, extracting solution ultrafiltration, concentrated, fill, and get final product.
The preparation of embodiment 3. powders
30 parts of 15 parts of Herba Violaes of Herba Taraxaci
3 parts of 9 parts of Radix Bupleuri of Poria
Pulverize, cross 100 mesh sieves, packing, and get final product.
Claims (3)
1. acne therapeutic agent is characterized in that being prepared from by the crude drug of following weight portion:
Herba Taraxaci 9-15 part Herba Violae 15-30 part
Poria 9-15 part Radix Bupleuri 3-9 part.
2. a kind of acne therapeutic agent as claimed in claim 1, is characterized in that also containing edible or pharmaceutic adjuvant.
3. as any one described a kind of acne therapeutic agent of claim 1-2, it is characterized in that the former powder of raw material or extract, directly or again add edible or pharmaceutic adjuvant, be prepared into capsule, tablet, granule, oral liquid, powder, teabag etc.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013100592688A CN103099903A (en) | 2013-02-26 | 2013-02-26 | Acne therapeutic preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013100592688A CN103099903A (en) | 2013-02-26 | 2013-02-26 | Acne therapeutic preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103099903A true CN103099903A (en) | 2013-05-15 |
Family
ID=48308315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2013100592688A Pending CN103099903A (en) | 2013-02-26 | 2013-02-26 | Acne therapeutic preparation |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103099903A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109771625A (en) * | 2017-11-15 | 2019-05-21 | 广西西林县农本生物科技有限公司 | A kind of Chinese medicine composition for treating acne |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000095648A (en) * | 1998-09-24 | 2000-04-04 | Tsumura & Co | Testosterone 5alpha-reductase inhibitor |
CN101313960A (en) * | 2008-07-17 | 2008-12-03 | 王跃进 | Lozenge for preventing and controlling whelk |
KR20100061090A (en) * | 2008-11-28 | 2010-06-07 | (주)아모레퍼시픽 | Cosmetic composition for abirritating or treating acne and contact eruption |
CN102716268A (en) * | 2012-06-18 | 2012-10-10 | 荣成市商贸城卫生所 | Traditional Chinese medicine composite for treating acne |
CN102805174A (en) * | 2011-05-31 | 2012-12-05 | 夏乐敏 | Health-care tea bag for preventing and treating whelk |
-
2013
- 2013-02-26 CN CN2013100592688A patent/CN103099903A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000095648A (en) * | 1998-09-24 | 2000-04-04 | Tsumura & Co | Testosterone 5alpha-reductase inhibitor |
CN101313960A (en) * | 2008-07-17 | 2008-12-03 | 王跃进 | Lozenge for preventing and controlling whelk |
KR20100061090A (en) * | 2008-11-28 | 2010-06-07 | (주)아모레퍼시픽 | Cosmetic composition for abirritating or treating acne and contact eruption |
CN102805174A (en) * | 2011-05-31 | 2012-12-05 | 夏乐敏 | Health-care tea bag for preventing and treating whelk |
CN102716268A (en) * | 2012-06-18 | 2012-10-10 | 荣成市商贸城卫生所 | Traditional Chinese medicine composite for treating acne |
Non-Patent Citations (2)
Title |
---|
王威等,: "柴胡二丁汤临床治验举隅", 《河北中医》 * |
石赟: "《中老年自我治病奇效方集锦·实用偏方》", 31 October 2006, 中医古籍出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109771625A (en) * | 2017-11-15 | 2019-05-21 | 广西西林县农本生物科技有限公司 | A kind of Chinese medicine composition for treating acne |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017372976B2 (en) | Compositions comprising sulfated polysaccharides | |
Gupta | The efficacy of Euphorbia prostrata in early grades of symptomatic hemorrhoids–a pilot study. | |
CN103099904A (en) | Traditional Chinese medicine preparation | |
CN103417683A (en) | Health food capable of reducing blood sugar | |
CN103083622A (en) | Compound preparation | |
CN101804105B (en) | Medicine composition for treating mammitis and preparation method thereof | |
CN103099905A (en) | Spleen deficiency and dampness abundance type acne treatment drug | |
CN103099878A (en) | Medicament for treating acne caused by liver qi stagnation | |
CN103393980A (en) | Quick and effective hemostasis traditional Chinese medicine tincture | |
CN103083580A (en) | Medical formula | |
CN104510853B (en) | A kind of Chinese medicinal effective-part composition for the treatment of dysmenorrhes and uses thereof | |
CN103099903A (en) | Acne therapeutic preparation | |
CN101474192A (en) | Veramyst medicinal preparation and preparation method | |
CN103099931A (en) | Pharmaceutical composition | |
CN103099930A (en) | Preparation for treating acne | |
CN106421075B (en) | A kind of preparation method and application of bamboo willow antioxidant activity component | |
CN103908484A (en) | Tripterygium wilfordii plastic for treating rheumatoid arthritis and preparation method thereof | |
CN103100062A (en) | Traditional chinese medicine composition | |
CN103083581A (en) | Medicament for treating spleen deficiency and damp abundance acnes | |
CN107007614A (en) | The medical usage of cycloastragenol | |
CN104510854B (en) | A kind of Chinese medicine composition for the treatment of dysmenorrhes and uses thereof | |
JPH02152926A (en) | Brain edema depressant | |
CN106943390B (en) | Application of the Strychnos nux-vomica aglycon in preparation prevention or treatment antiarrhythmic medicament | |
CN103110654A (en) | Acne treatment cream | |
CN103446288A (en) | Health food for prevention and treatment of diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130515 |